Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331226 | 1.00 | BLM (0.32) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL60910 | 0.84 | BLM (0.31) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL60909 | 0.84 | BLM (0.31) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL3291889 | 0.84 | HRH4 (0.32) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL163221 | 0.83 | BLM (0.47) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL59406 | 0.83 | BLM (0.47) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL59405 | 0.83 | BLM (0.47) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL10713853 | 0.83 | BLM (0.30) | BLMSMN1; SMN2HIF1A | |
| SCHEMBL26913087 | 0.83 | BLM (0.30) | BLMSMN1; SMN2HIF1A | |
| Hydrochloric Acid SCHEMBL2808246 | 0.81 | BLM (0.46) | BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010735-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR AMYOTROPHIC LATERAL SCLEROSIS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-8946148-B2 | Modified insulin polypeptides and their uses | AMBRX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20100298212-A1 | Modified Insulin Polypeptides and Their Uses | AMBRX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298212-A1 | Modified Insulin Polypeptides and Their Uses | IAPP, INSR, IGFBP4 | BLM 3006/4885SMN1; SMN2 1320/4885HIF1A 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.